Comparative Study on the Payment of Medical Insurance for Innovative Drugs Between China and Foreign Countries
10.3870/j.issn.1004-0781.2024.03.026
- VernacularTitle:中外创新药物医保支付的比较研究
- Author:
Fei YU
1
;
Jing LU
;
Chenxu GAO
;
Jingwei LI
Author Information
1. 北京大学第一医院医保处,北京 100034
- Keywords:
Innovative drugs;
Medical insurance payment;
Diagnosis related groups(DRG);
Policy recommendations
- From:
Herald of Medicine
2024;43(3):470-476
- CountryChina
- Language:Chinese
-
Abstract:
Payment by diagnosis related groups(DRG)is an important research direction in China's current medical insurance payment reform.However,it limits the clinical development and utilization of innovative medicines to a certain extent.Additional payments for innovative medicines have been thoroughly studied in many countries.This paper conducted an analysis and summary of the global experience regarding additional payment for innovative medicines under the DRG payment system.U-sing the United States,France,and Germany as case studies,this paper also examined the current state of medical insurance pay-ment for innovative medicines in China and the influence of DRG payment on the development of such medicine.In addition,it has put forward explicit policy recommendations,including the establishment of inclusion criteria,the selection of appropriate payment modes,the implementation of dynamic adjustment mechanisms,the enhancement of payment methods,etc.This paper aims to provide references to comprehensively promote DRG payment reform while further establishing and enhancing medical in-surance payment mechanisms related to innovative medicines in the context of China's national conditions.
